Alseres Pharmaceuticals, Inc. (ALSE)
Alseres Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Auburndale, MA, US. The stock last traded at $0.01, up 100.00% on the session, giving a market capitalisation of $398,255. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -198.8%. Its beta of 0.21 implies it has historically moved less than the broad market.
Alseres Pharmaceuticals, Inc. focuses on creating both diagnostic and therapeutic solutions, with a primary emphasis on ailments affecting the central nervous system. Their flagship experimental compound is Altropane, a molecular imaging agent developed for identifying and diagnosing Parkinson's disease and dementia. Founded in 1972, the company was previously known as Boston Life Sciences, Inc. before officially changing its name to Alseres Pharmaceuticals, Inc. in June 2007. Its operations are headquartered in Auburndale, Massachusetts.
Alseres Pharmaceuticals, Inc. is most often compared with the following Healthcare names: